The Conquering Cancer Initiative is a scientific and philanthropic initiative at the Salk Institute. Focusing on the hardest cancers to treat, Salk scientists are unlocking foundational knowledge that will help in treating all cancers.
A definition of translational research is integrating fundamental scientific discoveries and patient-oriented research with a long-term aim of improving human health.
The Salk Cancer Center, an NCI-Designated Basic Laboratory Cancer Center, strives to move research discoveries from the basic science laboratory into preclinical studies and advanced stages of development to help in the prevention, diagnosis, and treatment of human disease. Translating early discoveries into clinical trials is complex and requires significant funding and a longer timeframe to complete. For most philanthropic donors, private foundations, and public funding streams, this process is not a priority due to cost and the time to realize a benefit. The result is that many discoveries that can improve human health cannot receive the investments needed to see a beneficial outcome.
Advancing Salk science is our goal, and creating an opportunity to maximize the benefit to human health from the discoveries made in Salk labs is fundamental to our mission. Scientists from the Salk Cancer Center collaborate daily with clinicians at UC San Diego, City of Hope, and sister cancer centers worldwide. These collaborations allow Salk scientists to access patient samples and data for research purposes, design and run clinical trials to test the efficacy of potential treatments and advance successful discoveries into products or tools to improve patient care and health outcomes.
The Cancer Center Translational Fund
By creating the new Translational Fund through philanthropic support, the Salk Institute will be able to bolster a select number of outstanding projects and de-risk early discoveries towards commercial readiness and into valuable assets that will be partnered with industry. Through translational development, we expect to reach milestones that demonstrate the value or reduce the risk of Salk innovations to potential industry partners or investors that will help be the channels to advance Salk innovations into the marketplace. The Translation Fund will build on Salk’s continued success of bringing discoveries to benefit the public good ensuring and ensure we capture greater value for the Institute and our scientific teams with the added benefit of building a sustainable program of funding for future innovations.
Philanthropic support for the Translational Fund is an essential part of our mission to change the world for the better. By investing in the long-term scientific research conducted through the Cancer Center at the Salk Institute, you can help shape the future of human health.Donate to the Cancer Center Translational Discovery Fund
SEMINAR: Cancer Center Trainee Research Seminar
WHEN: Wednesday, September 20, 2023 at 9:30 a.m.
SPEAKER: Shira Yomtoubian, PhD (Shaw Lab)
TALK TITLE: Deciphering the role of AMPK in Pancreatic Cancer
SPEAKER:Queralt Vallmajo Martin, PhD (Wahl Lab)
TALK TITLE: The molecular landscape of injury-induced mammary epithelial cell fate switching
HOST: Geoff Wahl, Reuben Shaw
LOCATION: Conrad T. Prebys Auditorium
Tim Schoen, Chair
Daniel C. Lewis
Susan Pidgeon Mandel
Reuben Shaw, PhD
Cancer Center Director
Did you know that Salk Cancer Center has been leading the way in conquering cancer since 1970? Find Out How »
2022 Padres Pedal the Cause
The entire Padres Pedal the Cause community came together for an incredible year of fundraising and the highest amount raised to date. In 2022, over 2,200 participants including survivors, fighters, family and friends, children, doctors, scientists, and volunteers came together to raise over $3,209,520.00 to fund innovative, life-saving cancer research in San Diego.
2023 Padres Pedal the Cause
Congratulations to yet another successful fundraising event at Petco Park that included cycling, spin classes, 5K, Kids’ Challenge, inspirational stories, new friends, and renewed commitments to cancer research in San Diego. We look forward to Curebound’s announcement for final proceeds.